Jyong Biotech (MENS) vs Upstream Bio (UPB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Upstream Bio (UPB) has outperformed Jyong Biotech (MENS) over the past year, losing 86.8% versus a loss of 96.9%. Upstream Bio is the larger company by market cap ($151.2 million vs $139.9 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MENS | UPB |
|---|---|---|
| Share price | $1.84 | $2.76 |
| Market cap | $139.89M | $151.17M |
| 1-day change | -7.07% | -18.10% |
| YTD return | -53.42% | -89.83% |
| 1-year return | -96.88% | -86.84% |
| EPS (TTM) | $-0.06 | $-2.88 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $2.85M |
| Revenue growth (YoY) | — | +20.42% |
| Net income (latest FY) | $-4.67M | $-143.44M |
| Operating margin | — | -5618.82% |
| Net margin | — | -5026.03% |
| 52-week high | $63.00 | $33.68 |
| 52-week low | $1.43 | $2.74 |
| Distance from 52-week high | -97.08% | -91.81% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +1028.26% |
| Average volume | 45.46K | 734.05K |
| Shares outstanding | 74.23M | 54.77M |
| Employees | 27 | 75 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- UPB has outperformed MENS by 10.0 percentage points over the past year.
About Jyong Biotech
MENS stock →Jyong Biotech Ltd., a science-driven biotechnology company, engages in the development and commercialization of plant-derived drugs for the treatment of urinary system diseases in the United States, the European Union, and Asia. It develops Botreso, for the treatment of benign prostate hyperplasia/lower urinary tract symptoms; PCP for treating prostate cancer; and interstitial cystitis (IC) for the treatment of IC/bladder pain syndrome.
Health Care · Biotechnology: Pharmaceutical Preparations · 27 employees
About Upstream Bio
UPB stock →Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease and in Phase I clinical trial for treating chronic obstructive pulmonary disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 75 employees
MENS vs UPB FAQ
Which is bigger, Jyong Biotech or Upstream Bio?
Upstream Bio (UPB) is larger, with a market capitalization of $151.17M compared with $139.89M for Jyong Biotech (MENS).
Which stock has performed better over the past year, MENS or UPB?
UPB returned -86.84% over the past 12 months, compared with -96.88% for MENS (price return, excluding dividends). Past performance does not predict future results.
Are Jyong Biotech and Upstream Bio in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.